| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.1 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.079 | 0.1 |